Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis

Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. However, results of phase II and III clinical trials assessing ICIs plus chemotherapy as neoadjuvant treatment were controversial and conflicting. We p...

Full description

Bibliographic Details
Main Authors: Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cells
Subjects:
breast cancer
pembrolizumab
atezolizumab
durvalumab
immunotherapy
neoadjuvant
Online Access:https://www.mdpi.com/2073-4409/11/12/1857

Internet

https://www.mdpi.com/2073-4409/11/12/1857

Similar Items